Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant tech. company of fraudulent practices, including kickbacks, billing fraud, ...
TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...
Boston, Massachusetts-- (Newsfile Corp. - January 15, 2025) - Berman Tabacco announces that it is investigating potential securities law violations by TransMedics Group, Inc. ("TransMedics" or the ...
Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...
TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as ...
TransMedics has previously touted its OCS as "the only FDA approved, portable, multi-organ, warm perfusion technology platform" and its NOP as providing a more efficient organ procurement process.
The law firm of Kirby McInerney LLP is investigating potential claims against TransMedics Group, Inc. (“TransMedics” or the“Company”) (NASDAQ:TMDX). The investigation concerns whether TransMedics ...
Scorpion Capital has assigned a target price of $0 to TransMedics stock, suggesting the firm believes the company’s alleged misconduct poses an existential threat. Hagens Berman’s ...
Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came after activist short seller Scorpion Capital released a scathing report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback